Your browser doesn't support javascript.
loading
Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration.
Perry, Matthew W D; Björhall, Karin; Bonn, Britta; Carlsson, Johan; Chen, Yunhua; Eriksson, Anders; Fredlund, Linda; Hao, Hai'e; Holden, Neil S; Karabelas, Kostas; Lindmark, Helena; Liu, Feifei; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist, Sandra; Smith, Reed W; Svensson, Tor; Terstiege, Ina; Tyrchan, Christian; Yang, Wenzhen; Zhao, Shuchun; Öster, Linda.
Affiliation
  • Perry MWD; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Björhall K; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Bonn B; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Chen Y; Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA, Beijing 100176, P.R. China.
  • Eriksson A; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Hao H; Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA, Beijing 100176, P.R. China.
  • Holden NS; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Karabelas K; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Liu F; Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA, Beijing 100176, P.R. China.
  • Pemberton N; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Rodrigo Blomqvist S; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Smith RW; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Svensson T; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Terstiege I; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Tyrchan C; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Yang W; Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA, Beijing 100176, P.R. China.
  • Zhao S; Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA, Beijing 100176, P.R. China.
J Med Chem ; 60(12): 5057-5071, 2017 06 22.
Article in En | MEDLINE | ID: mdl-28520415
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Structure-Activity Relationship / Enzyme Inhibitors / Phosphoinositide-3 Kinase Inhibitors Limits: Animals Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2017 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Structure-Activity Relationship / Enzyme Inhibitors / Phosphoinositide-3 Kinase Inhibitors Limits: Animals Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2017 Document type: Article Affiliation country: